Wolowacz SE, Petrillo J, Doward LC, Briggs A. Measuring health-state utility values in clinical trials: can we do better? Ispor Connections. 2014 Sep;20(5):4-8.
Stull DE, Houghton KF, Petrillo J. Innovative data analysis for demonstrating product value: analysis of heterogeneity in treatment response in clinical trials. Ispor Connections. 2013;19(1):5-8.
Masters E, Zlateva G, Harris NI. Real-world data for use in the real world: the pain paradigm. Ispor Connections. 2013;19(2):9-11.
Leiss JK, Lyden JT, Mathews R, Sitzman KL, Vanderpuije A, Mav D, Kendra MA, Klein C, Humphrey CJ. Blood exposure incidence rates from the North Carolina study of home care and hospice nurses. Am J Ind Med. 2009 Feb 1;52(2):99-104.
Wolowacz SE, Khan SB. The New National Institute of Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process: experience from the first completed appraisals. Ispor Connections. 2007;13(2):12-5.
Lanes SF, Rothman KJ, Dreyer NA, Soden K. Mortality among workers exposed to glycerol polyglicidyl ether. Am J Ind Med. 1994 May;25(5):689-96. doi: 10.1002/ajim.4700250508
Lanes SF, Rothman KJ, Soden KJ, Amsel J, Dreyer NA. Mortality among synthetic-fiber workers exposed to glycerol polyglycidyl ether. Am J Ind Med. 1994 Jan 1;25(5):689-96.